Open AccessProgrammed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer
Author(s) -
Akito Hata,
Nobuyuki Katakami,
Shigeki Nanjo,
Chiyuki Okuda,
Ryuji Kaji,
Katsuhiro Masago,
Shiro Fujita,
Hiroshi Yoshida,
Kota Zama,
Yukihiro Imai,
Yukio Hirata
Publication year - 2017
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.22837
Subject(s) - medicine , epidermal growth factor receptor , lung cancer , immunohistochemistry , oncology , cancer , pathology , cancer research
Current clinical trials have suggested poorer efficacies of anti-programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) immunotherapies for non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor ( EGFR ) mutations, implying lower PD-L1 expression in EGFR -mutant NSCLC than in EGFR -wild type.